$32.38 +0.61 (%) Acorda Therapeutics Inc - NASDAQ

Oct. 20, 2014 | 04:00 PM

Partner Headlines

  1. Benzinga's M&A Chatter for Wednesday September 24, 2014

    Benzinga | Sep. 24, 2014 | 21:09PM EST
  2. Acorda up on Civitas purchase

    IBD | Sep. 24, 2014 | 18:14PM EST
  3. Stocks Gain While Dollar Reaches Highest Level Since 2010

    Benzinga | Sep. 24, 2014 | 17:03PM EST
  4. Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results

    Benzinga | Sep. 24, 2014 | 15:54PM EST
  5. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD | Sep. 24, 2014 | 13:27PM EST
  6. U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast

    Benzinga | Sep. 24, 2014 | 13:17PM EST
  7. Markets Edge Lower; KB Home Posts Downbeat Results

    Benzinga | Sep. 24, 2014 | 10:49AM EST
  8. Benzinga's Volume Movers

    Benzinga | Sep. 24, 2014 | 10:14AM EST
  9. Morning Market Movers

    Benzinga | Sep. 24, 2014 | 09:40AM EST
  10. Events for the Week of Sept. 8-12

    Benzinga | Sep. 10, 2014 | 14:34PM EST
  11. Actavis Fuels Growth With Acquisitions, New Generics

    IBD | Jul. 14, 2014 | 17:30PM EST
  12. Markets Edge Higher; Alcoa Profit Beats Street View

    Benzinga | Jul. 9, 2014 | 10:20AM EST
  13. Benzinga's Volume Movers

    Benzinga | Jun. 18, 2014 | 10:17AM EST
  14. Market Wrap For June 17: Markets Higher Ahead Of Fed Decision

    Benzinga | Jun. 17, 2014 | 16:30PM EST
  15. Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session

    Benzinga | Jun. 17, 2014 | 15:16PM EST
  16. Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics Shares Tumble

    Benzinga | Jun. 17, 2014 | 12:41PM EST
  17. Mid-Morning Market Update: Markets Gain; FactSet Posts Rise In Revenue

    Benzinga | Jun. 17, 2014 | 10:27AM EST
  18. Morning Market Losers

    Benzinga | Jun. 17, 2014 | 09:55AM EST
  19. Citigroup downgraded Acorda Therapeutics, Says Fundamentals Have Reversed For the Near-Term

    Benzinga | Jan. 6, 2014 | 12:10PM EST
  20. Acorda Therapeutics Announces European Patent Office Upholds Fampridine Patent

    Benzinga | Dec. 19, 2013 | 07:02AM EST
  21. Acorda Presents New Diazepam Nasal Spray Data at 67th Annual Meeting of American Epilepsy Society

    Benzinga | Dec. 9, 2013 | 07:11AM EST
  22. Acorda Therapeutics Reports Data from Phase 2 Trial of Delfampridine-ER, Says Data Consistent with Prior Trials

    Benzinga | Oct. 14, 2013 | 07:58AM EST
  23. Acorda Therapeutics Could Be a Stock to Watch in 2013

    Benzinga | Feb. 4, 2013 | 08:21AM EST
  24. UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts

    Benzinga | Jan. 3, 2013 | 01:26AM EST
  25. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 21, 2012 | 00:17AM EST
  26. Acorda Therapeutics, Inc. (ACOR) CFO David Lawrence sells 9,313 Shares

    GuruFocus | Dec. 5, 2012 | 11:06AM EST
  27. Acorda Therapeutics, Inc. (ACOR) President and CEO Ron Cohen sells 16,407 Shares

    GuruFocus | Dec. 5, 2012 | 10:36AM EST
  28. Acorda Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 11:36AM EST
  29. Acorda Therapeutics Names Jane Wasman President, International

    Benzinga | Oct. 9, 2012 | 00:39AM EST
  30. UPDATE: Aegis Capital Corp Initiates Buy on Acorda Therapeutics on Ampyra Visibility

    Benzinga | Aug. 21, 2012 | 07:07AM EST
  31. Tesoro, Focus Media Among Stocks Up on High Volume Monday

    FoxBusiness | Aug. 13, 2012 | 06:33AM EST
  32. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 13, 2012 | 02:21AM EST
  33. Acorda Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 8, 2012 | 14:29PM EST
  34. Health Care Sector Wrap

    FoxBusiness | Jul. 2, 2012 | 10:51AM EST
  35. From Earlier: Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits

    Benzinga | Jun. 12, 2012 | 03:19AM EST
  36. A Peek Into The Market Before The Trading Starts

    Benzinga | Jun. 12, 2012 | 01:33AM EST
  37. Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits

    Benzinga | Jun. 12, 2012 | 01:19AM EST
  38. UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk

    Benzinga | May. 18, 2012 | 06:50AM EST
  39. Acorda Therapeutics Inc. Reports Operating Results (10-K)

    GuruFocus | Feb. 28, 2012 | 11:19AM EST
  40. Acorda Therapeutics Announces Launch of Authorized Generic Version of ZANAFLEX CAPSULES®

    Benzinga | Feb. 6, 2012 | 09:15AM EST
  41. 5 Speculative Biotech Stocks to Consider Buying Now

    GuruFocus | Jan. 24, 2012 | 11:09AM EST
  42. JP Morgan Downgrades ACOR, ALTH, AMGN, VPHM

    Benzinga | Jan. 23, 2012 | 00:48AM EST
Trading Center